Skip to Content

Dapagliflozin / Saxagliptin Dosage

Applies to the following strengths: 10 mg-5 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Diabetes Type 2

Dapagliflozin 10 mg/saxagliptin 5 mg orally once a day in the morning

-Volume depletion should be corrected prior to initiation.
-This combination product should only be used in patients who tolerate dapagliflozin 10 mg per day.

Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who have inadequate control with dapagliflozin or who are already treated with dapagliflozin and saxagliptin.

Renal Dose Adjustments

Moderate to severe renal impairment (eGFR less than 45 mL/min/1.73 m2): Contraindicated

Moderate renal impairment (eGFR less than 60 mL/min/1.73 m2): Do not initiate therapy
If eGFR falls persistently below 60 mL/min/1.73 m2: Therapy should be discontinued

Liver Dose Adjustments

Use with caution, especially in patients with severe hepatic impairment.

Benefit-risk for use in severe hepatic impairment should be individually assessed since safety and efficacy in this population has not been studied.

Dose Adjustments

Elderly: Dose adjustment may be required due to renal function

Concomitant Use with Strong CYP450 3A4/5 Inhibitors: Not Recommended
Examples: Ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.



Other Comments

Administration advice:
-Take orally once a day in the morning with or without food
-Tablet should not be split or cut

-Missed dose: If a dose is missed, take the next dose as prescribed, unless otherwise instructed by healthcare provider; patients should not take an extra dose the next day

-Correct volume depletion prior to initiating treatment.
-Not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
-Consider the risk and benefits of therapy in patients who have known risk factors for heart failure.

-Assess fluid status prior to initiation and monitor for signs and symptoms of volume depletion during therapy.
-Verify renal function at baseline, and monitor periodically during therapy.
-Monitor for signs and symptoms of acute kidney injury.
-Monitor for LDL-C per standard of care.
-Evaluate for the presence of acidosis, including ketoacidosis in symptomatic patients, even if blood sugar is below 250 mg/dL.
-Monitor blood glucose and HbA1c
-Monitor for signs and symptoms of heart failure
-Monitor for signs and symptoms of pancreatitis.

Patient advice:
-Patients should understand that while taking this drug they need to be sure to maintain adequate fluid intake to avoid adverse reactions related to volume depletion.
-Patients should understand the importance of adhering to dietary instructions and regular physical activity; they should be able to recognize the signs and symptoms of high and low blood sugar and know how to treat.
-During periods of stress such as fever, trauma, infection, or surgery, management of diabetes may change and patients should be advised to seek medical advice.
-Patients should understand that this drug will cause their urine to test positive for glucose.
-Patients experiencing symptoms of ketoacidosis such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue, or sleepiness should be instructed to seek immediate medical attention.
-Patients should be instructed to seek medical attention promptly for signs and symptoms of acute kidney injury such as decreased urine, swelling in the legs or feet.
-Patients should be informed that acute pancreatitis, heart failure, allergic reactions, bladder cancer, bullous pemphigoid, genital mycotic infections, serious urinary tract infections, severe and persistent joint pain have occurred; they should understand the importance of reporting signs and symptoms of these conditions and when to promptly seek medical attention.
-Patients who become pregnant, are planning to become pregnant, or are breastfeeding should speak with their healthcare provider.